15 April 2023
Latham & Watkins Advises Goldman Sachs Asset Management in US$158 Million Series B Financing for TORL BioTherapeutics
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Saad Khanani Lead | Latham & Watkins LLP | Partner | Not stated | Bay Area |
| Omar Ammash | Latham & Watkins LLP | Associate | Not stated | Chicago |
| Jay Trewn | Latham & Watkins LLP | Associate | Not stated | Chicago |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| Alex Farris | Latham & Watkins LLP | Associate | tax | Not stated |
| Julie Crisp | Latham & Watkins LLP | Partner | benefits & compensation | Century City/Bay Area |
Stated terms
- Stated value
- USD 158m (US$158 million)
- What the figure measures
- Issue size
- Client
- Goldman Sachs Asset ManagementInvestor
- Counterparties
- TORL BioTherapeutics LLC (Issuer)
UC, Office of the Chief Investment Officer (Investor)
Bristol Myers Squibb (Investor)
Deep Track Capital (Investor)
Vertex Ventures HC (Investor)
Moore Strategic Ventures (Investor)
Cowen Healthcare Investments (Investor)
Perceptive Xontogeny Venture Fund (Investor)
Alexandria Venture Investments (Investor)
OCV Partners (Investor)